PCV86 Cardiovascular Surgery Pathway Microsimulation Framework To Study The Health Economics Of Clevidipine  by Schwenkglenks, M. et al.
 VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 1 - A 2 9 5  A117
direct medical costs were considered. [3] The model used a lifetime horizon with 
a 5% discount. Results: Of all therapies, Apixaban is the only one that improved 
outcomes in number of Strokes (4), MI (3), Bleedings (85) and Systemic Embolism 
events (1) prevented when compared to Warfarin. Overall costs were US$19007.24, 
US$24615.16, US$24137.36, US$23510.21, and US$25067.11 for Warfarin, Apixaban, 
Dabigatran 110 mg, Dabigatran 150 mg and Rivaroxaban respectively. In terms of 
QALY’s, Apixaban earned the highest amount with 5.736 while Warfarin has the low-
est reported of 5.566. In the CE incremental analysis, Apixaban was a cost-effective 
alternative to other anticoagulants. According to Trinidad’s Willingness to Pay (3 
GPB per capita), Apixaban obtained the highest probability of being cost-effective 
(70%). ConClusions: Apixaban is a Cost-Effective option for the Trinidad’s Private 
Health System.
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objeCtives: To determine the cost-effectiveness of apixaban compared to aspi-
rin to prevent thromboembolic events in patients with atrial fibrillation who are 
unsuitable or intolerant of warfarin therapy, from an Australian health care perspec-
tive. Methods: By extrapolating data from the Apixaban Versus Acetylsalicylic 
acid to prevent Stroke in Atrial Fibrillation (AVERROSE) trial, a Markov model with 
yearly cycles was developed to simulate the costs and effects of apixaban compared 
to aspirin over 10 years. The model comprised five health states: ‘Alive without 
thromboembolic disease (stroke, myocardial infarction and other systemic embo-
lism) nor major bleeding (MB)’; ‘Alive with thromboembolic disease, but without 
prior MB’; ‘ Alive without thromboembolic disease, but with prior MB’; ‘Alive with 
thromboembolic disease and prior MB’; and ‘Dead’. Costs, from an Australian health 
care perspective, were estimated from published sources. The main outcome of 
interest was incremental cost-effectiveness ratio (ICER) per quality adjusted life 
year (QALY) saved and per year of life saved (YoLS). Costs and benefits were dis-
counted at 5.0% per annum. Results: For each patient followed-up over 10 years, 
the model predicted that compared to aspirin, apixaban would lead to 0.19 YoLS 
(discounted) and 0.20 QALYs saved (discounted), at a net cost of AUD $5,025 (dis-
counted). This equated to ICERs of AUD $27,090 per YoLS and AUD $25,095 per QALY 
saved. One way and probabilistic sensitivity analyses indicated the results to be 
robust. ConClusions: Compared to aspirin, apixaban is likely to be cost-effective 
in preventing thromboembolic disease among patients with atrial fibrillation who 
are intolerant to warfarin.
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objeCtives: Clevidipine, a short-acting, intravenous dihydropyridine calcium chan-
nel blocker, is easily titratable to achieve the desired blood pressure (BP). The ECLIPSE 
trials compared the safety and efficacy of clevidipine to sodium nitroprusside, nitro-
glycerin, and nicardipine during the perioperative period in cardiac surgery patients. 
We sought to gain an initial understanding of economic properties. Methods: A 
decision-analytic microsimulation framework was defined to follow patients from 
hospital admission; assigned characteristics reflected the pooled ECLIPSE popula-
tions (1,511 coronary artery bypass graft and/or valve surgery patients aged 19-89 
years). Exploratory multivariate regression analyses of the ECLIPSE data identified 
potential clinical and economic effects of clevidipine. Additional inputs came from 
administrative databases and published sources. Costs were assessed from a US 
health system perspective. Unit costs for intensive care and normal ward covered 
room and board costs only. Economic endpoints included cost per death avoided 
at day 30 and cost per quality-adjusted life year (QALY) gained. A life-long time 
horizon was adopted for the latter; costs and effects were discounted by 3% per 
year. Results: BP control was significantly associated with time to extubation and 
30-day occurrence of bleeding, renal insufficiency, death; associations with other 
clinical events, length of stay were non-significant. At day 30, clevidipine dominated 
comparators. Costs ranged from USD14,718 (clevidipine) to USD15,787 (nicardipine). 
Probability of survival varied slightly between agents; from 96.8% (clevidipine) to 
96.4% (sodium nitroprusside). For the life-long time horizon, clevidipine showed 
an incremental cost-effectiveness of USD10,863 per QALY gained versus sodium 
nitroprusside. Nitroglycerin and nicardipine were dominated. ConClusions: Our 
framework provides a flexible basis for assessing economic properties of clevidipine 
use in cardiac surgery. The effects implemented to-date, driving economic results, 
come from unplanned, exploratory analyses and require independent, ideally 
prospective verification. Current numerical results, including cost savings, should 
therefore be interpreted as indicative of potential but highly tentative.
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objeCtives: Recently, “2014 evidence-based guideline for the management of high 
blood pressure in adults” was published by the Eighth Joint National Committee 
(JNC 8), in which the threshold of initiate pharmacologic treatment to lower blood 
pressure at systolic blood pressure (SBP) was increased from 140 to 150 mmHg. 
Considering the scarcity of economic evaluation of threshold for initial hyperten-
sion treatment, the aim of this study was to evaluate whether the new threshold of 
initial hypertension treatment is cost-effective compared to the former one from a 
third party payer perspective. Methods: A state-transitional model was built using 
published evidence comparing the quality adjusted life years (QALYs) patients 60 
years or older gained using different threshold of initial hypertension treatment. 
The QALYs and occurrence of CVD were used as primary and secondary outcome. 
The model used a life-time framework adopting a third-party payer’s perspective. 
Incremental cost-effectiveness ratio (ICER) between groups was calculated in U.S. 
dollars per QALY gained. Both one-way sensitivity analyses and probabilistic sen-
sitivity analysis were conducted to explore the uncertainty of variables. Results: 
The ICER for the base case of the new guideline versus the original one was 30,298 
U.S. dollars per QALY gained. Other than age of patients, there is no variable could 
significantly influence results. There would be a 32% of more effective and less 
costly using new guideline threshold, and overall 83% chance of being cost-effective 
compared with the original one. ConClusions: The results indicated that it high 
likely that the new guideline of threshold for initial hypertension treatment is cost-
effective than the original one, which means for patients older than 60 years diag-
nosed with hypertension, the initial anti-hypertension treatment could be given 
till the SBP comes to 150 mmHg.
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objeCtives: Assess the cost-effectiveness of ambrisentan versus bosentan for 
treatment of pulmonary arterial hypertension in patients with OMS functional class 
III for knowing which treatment has superior efficiency. Methods: We performed 
a cost-effectiveness analysis using a Markov model. It has involved the treatment of 
a patient older than 50 years, which has continued until he had completed 80 years 
and compared the results obtained in a patient treated with bosentan and another 
patient treated with ambrisentan. The transition probabilities between different 
health states considered in the model were taken from the literature review and 
estimated for each cycle of the model. To evaluate the drug price effect and vari-
ations of effectiveness on results, we developed a sensitivity analysis Montecarlo 
type. Results: In the base case, the ambrisentan was more cost-effective than 
bosentan, with an approximate cost of $ 53.146,41 (USD) for each year of life free 
of disease versus $ 61.040,93 (USD) for year of life free of disease for bosentan. 
The incremental cost-effectiveness ratio by patient was $ 143.505,23 (USD). The 
variable that more affected the final result was the drug price. Sensitivity analysis 
showed that the model is robust, and to changes in price and efficacy of the drug 
the results are stable, and ambrisentan remains cost-effective. ConclusionSWith the 
data obtained in the study the use of ambrisentan in the treatment of pulmonary 
arterial hypertension in Colombia is presented as an efficient alternative despite 
currently the bosentan is reimbursed
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objeCtives: Acenocoumarol, a vitamin K antagonist (VKA) is the standard of 
care for stroke prevention in patients with atrial fibrillation (AF) in Chile. While 
ARISTOTLE enrolled warfarin as a comparator, evidence is deemed applicable to 
patients treated with acenocoumarol (called as VKA hereafter) in Latin America and 
Southern Europe. Nevertheless, Apixaban is the only novel oral anticoagulant that 
has demonstrated significant benefit in terms of efficacy and safety against war-
farin in ARISTOTLE. The aim of this study is to estimate the cost-effectiveness (CE) 
of Apixaban versus VKA in Non Valvular Atrial Fibrillation (NVAF) from the public 
payer perspective in Chile. Methods: A Markov model was adapted to evaluate 
the clinical and economic impact of Apixaban compared to VKA in VKA-suitable 
population over lifetime. Effectiveness data were derived from the original clinical 
trials. Clinical events captured include ischemic and hemorrhagic stroke (further 
categorized as mild, moderate or severe), intracranial hemorrhage (ICH), other major 
bleed, clinically relevant non-major bleed, myocardial infarction, cardiovascular 
hospitalization and deaths. Benefit assessment was conducted using a patient pref-
erence study using EQ-5D. The model was imputed the parameters of local costs and 
utilities, and Chilean epidemiology data. Associated direct medical costs were taken 
from local databases; discounted at 3.5% per year, and expressed in 2013 CLP$ as of 
July. Results: The incremental cost of treating a patient with Apixaban vs VKA was 
CLP$ 1,964,424, providing an incremental effectiveness of 0.537 QALY. Therefore, the 
cost per QALY gained is CLP$ 3,967,325. Tornado analysis shows that results are most 
sensitive to stroke risk for Apixaban, followed by ICH risk for VKA ConClusions: 
Using accepted threshold for cost effectiveness of CLP$ 9,552,500 for Chilean market 
(1 GDP/capita), Apixaban was deemed as a very cost effective alternative to VKA for 
stroke prevention in non-valvular AF patients in Chile.
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objeCtives: Current standard treatment of pulmonary embolism (PE) in Canada 
involves a low molecular weight heparin (LMWH) and vitamin K antagonist (VKA). 
However, such treatment has limitations. Rivaroxaban, an oral factor Xa inhibitor, 
was recently approved approved by Health Canada for the treatment of venous 
thromboembolic events (VTE - deep vein thrombosis [DVT], pulmonary embolism 
[PE]) and prevention of recurrent DVT and PE. EINSTEIN-PE compared rivaroxaban 
to enoxaparin/VKA for 3, 6 or 12 months of treatment post-PE. Rivaroxaban was 
